Drugs / Vociprotafib
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04916236 | Mar 2022 → Jul 2024 | colorectal cancer, malignant pancreatic neoplasm, non-small cell lung carcinoma | The Netherlands Cancer Institute | Terminated | No outcome recorded |
| Phase 1 | NCT04185883 | Dec 2019 → Dec 2026 expected | cancer | Amgen | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03634982 | Sep 2018 → Mar 2023 | cancer | Revolution Medicines, Inc. | Unknown | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04418661 | Jun 2020 → Apr 2024 | metastatic neoplasm | Sanofi | Terminated | No outcome recorded |
| Phase 1/2 | NCT03989115 | Jul 2019 → Feb 2022 | cancer | Revolution Medicines, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05054725 | Dec 2021 → Jul 2024 | non-small cell lung carcinoma | Revolution Medicines, Inc. | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vociprotafib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04418661 ↗ |
| Known as | Ptpn11 inhibitor rmc-4630 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314427 ↗ |
| Known as | RMC-0694630 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314427 ↗ |
| Known as | RMC-4630 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05054725 ↗ |
| Known as | SAR-442720 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314427 ↗ |
| Known as | SAR442729 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314427 ↗ |
| Action | Inhibit | “* SHP2-inhibitor” NCT04916236 ↗ |
| Modality | Small molecule | — CHEMBL5314427 ↗ |
| Route | Oral | “RMC-4630 for oral administration” NCT03634982 ↗ |
| Target | PTPN11 | “inhibition of SHP2 (also known as PTPN11)” PMID 29808006 ↗ May 2018 |